ArticleJournal of neuro-oncology2020
Incidence of high grade gliomas presenting as radiographically non-enhancing lesions: experience in 111 surgically treated non-enhancing gliomas with tissue diagnosis.
Article in Journal of neuro-oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Dynamic glucose-enhanced MRI in brain tumors.Magma (New York, N.Y.) · 2026Review
- Development of a Prediction Model for Progression Risk in High-Grade Gliomas Based on Habitat Radiomics and Pathomics.Annals of clinical and translational neurology · 2026Article
- Investigating the Secreted Proteome of Primary and Metastatic Human Brain Tumour Explants Maintained on a Miniaturised Perfusion Device.Current oncology (Toronto, Ont.) · 2026Article
- Review
- Dynamic glucose enhanced imaging using direct water saturation.Magnetic resonance in medicine · 2025Article
- Clinical outcome and deep learning imaging characteristics of patients treated by radio-chemotherapy for a "molecular" glioblastoma.The oncologist · 2025Article
- ESR Bridges: imaging and treatment in brain tumours-a multidisciplinary view.European radiology · 2025Article
- Preoperative prediction of diffuse glioma type and grade in adults: a gadolinium-free MRI-based decision tree.European radiology · 2025Article
- Artificial intelligence prediction of nonenhancing brain tumor malignancy based onFrontiers in surgery · 2025Article
- Mechanical properties of pediatric low-grade gliomas in children with and without neurofibromatosis type 1.Neuroradiology · 2024Article
- Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas.Journal of neuro-oncology · 2023Review
- Article
- Three-dimensional arterial spin labeling-guided dose painting radiotherapy for non-enhancing low-grade gliomas.Japanese journal of radiology · 2023Article
- Therapy Defining at Initial Diagnosis of Primary Brain Tumor-The Role ofBiomedicines · 2023Article
- The diagnostic value of contrast enhancement on MRI in diffuse and anaplastic gliomas.Acta neurochirurgica · 2022Article
- Acute progression of cerebral amyloid angiopathy-related inflammation diagnosed by biopsy in an elderly patient: A case report.Surgical neurology international · 2022Article
- Three-Dimensional Arterial Spin Labeling-Guided Sub-Volume Segmentation of Radiotherapy in Adult Non-Enhancing Low-Grade Gliomas.Frontiers in oncology · 2022Article
- DCE-MRI in Glioma, Infiltration Zone and Healthy Brain to Assess Angiogenesis: A Biopsy Study.Clinical neuroradiology · 2021Article
- Can High b Value Diffusion Be a Surrogate Marker for PET-A MR/PET Study in Neurooncology Set Up.Frontiers in neurology · 2021Article
- Establishment and validation of a nomogram for predicting IDH-wildtype glioblastomas in nonenhancing adult-type diffuse gliomas.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAlthough non-enhancing lesions suspicious for glioma are usually assumed to be low grade glioma (LGG), some high grade glioma (HGG) do not enhance, which may lead to a delay in biopsy and/or resection, diagnosis, and treatment initiation. Thus, there is a clear need for a large-sample study that quantifies the rate of malignant, non-enhancing gliomas.
methodsWe retrospectively reviewed our series of 561 consecutive surgically treated gliomas with tissue diagnosis, 111 of which were non-enhancing, to determine the prevalence of high-grade histology in radiographically presumed LGG. Relative expression of tumor markers were also reported for non-enhancing lesions to investigate genetic correlates.
resultsWe identified 561 surgically treated gliomas with tissue diagnosis from August 2012 to July 2018 and found that 111 patients (19.8%) demonstrated non-enhancing lesions suspicious for glioma on preoperative MRI. Thirty-one (27.9%) of the non-enhancing lesions were classified as HGGs (WHO Grade III or IV). Non-enhancing lesions were four times more likely to be HGG in patients older than 60 years than patients younger than 35 years (41.2% vs. 11.4%, Pearson Chi
conclusionA clinically significant proportion (27.9%) of non-enhancing lesions were found to be HGG on final pathologic diagnosis. Thus, in patients with good functional and health status, especially those older than 60 years, we recommend obtaining tissue diagnosis of all lesions suspected to be glioma, even those that are non-enhancing, to guide diagnosis as well as early initiation of chemotherapy and radiation therapy.
Indexed as
Identifiers
32221785What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.